B
ENTA icon

Braidwell’s Enanta Pharmaceuticals ENTA Stock Holding History

Braidwell’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,038,310
Closed -$11.6M – 79
2023
Q3 		$11.6M Hold
1,038,310
– – 0.37% 72
2023
Q2 		$22.2M Hold
1,038,310
– – 0.73% 51
2023
Q1 		$42M Buy
1,038,310
+712,472
+219% +$34M 1.38% 27
2022
Q4 		$15.2M Buy
+325,838
New +$14.9M 0.51% 67

Other funds holding ENTA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Braidwell's ENTA Position: Q4 2023 in Review

Braidwell sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 1,038,310 shares — an estimated $11.6M sold.

Braidwell first reported a position in ENTA in Q4 2022 and held it in 4 quarters. The position peaked at $42M in Q1 2023. 106 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

  • Braidwell reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Braidwell sold 1,038,310 Enanta Pharmaceuticals shares in Q4 2023, an estimated $11.6M.
  • Braidwell first reported a position in Enanta Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Braidwell's Enanta Pharmaceuticals position peaked at $42M in Q1 2023.
  • 106 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on Braidwell's 13F filing for Q4 2023, filed 14 Feb 2024.